Verrica Pharmaceuticals Inc. (VRCA)
NASDAQ: VRCA · Real-Time Price · USD
0.694
+0.018 (2.65%)
At close: Dec 20, 2024, 4:00 PM
0.708
+0.014 (1.97%)
After-hours: Dec 20, 2024, 4:46 PM EST
Verrica Pharmaceuticals Revenue
Verrica Pharmaceuticals had revenue of $-1.78M in the quarter ending September 30, 2024, a decrease of -161.06%. This brings the company's revenue in the last twelve months to $9.21M, up 187.45% year-over-year. In the year 2023, Verrica Pharmaceuticals had annual revenue of $5.12M, down -43.27%.
Revenue (ttm)
$9.21M
Revenue Growth
+187.45%
P/S Ratio
3.51
Revenue / Employee
$92,100
Employees
100
Market Cap
62.87M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Outset Medical | 114.73M |
OptiNose | 75.67M |
InterCure | 72.42M |
Cryo-Cell International | 31.84M |
IceCure Medical | 3.67M |
VolitionRx | 1.29M |
VRCA News
- 12 days ago - Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 15 days ago - Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan - GlobeNewsWire
- 4 weeks ago - Verrica Announces Pricing of $42.0 Million Public Offering - GlobeNewsWire
- 4 weeks ago - Verrica Announces Proposed Public Offering - GlobeNewsWire
- 7 weeks ago - Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements - PRNewsWire
- 2 months ago - Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference - GlobeNewsWire
- 2 months ago - VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA - Business Wire
- 2 months ago - Verrica Pharmaceuticals Announces Restructuring of Commercial Organization - GlobeNewsWire